Repositorio Dspace

Listar por tema "Neoadjuvant Therapy"

Listar por tema "Neoadjuvant Therapy"

Ordenar por:Orden:Resultados:

  • Angiogenic role of miR-20a in breast cancer 
    Luengo-Gil, Ginés; González-Billalabeitia, Enrique; Alejo-Pérez-Henarejos, Sergio; Navarro-Manzano, Esther; Chaves-Benito, Asunción; García-Martínez, Elena; García-Garre, Elisa; Vicente, Vicente; Ayala-de-la-Peña, Francisco (PUBLIC LIBRARY SCIENCE, 2018-04-04)
    BACKGROUND: Angiogenesis is a key process for tumor progression and a target for treatment. However, the regulation of breast cancer angiogenesis and its relevance for clinical resistance to antiangiogenic drugs is still ...
  • Assessing tumor response to neoadjuvant chemoradiation in rectal cancer with rectoscopy and 18F-FDG PET/CT: results from a prospective series 
    López-López, Víctor; Abrisqueta, Jesús; Luján, Juan; Lynn, Patricio-B; Frutos, Laura; Ono, Akiko; Ortiz, Eduardo; López-Espin, José-J; Gil, José; Parrilla-Paricio, Pascual (Arán Ediciones, 2021)
    INTRODUCTION: rectoscopy and 18F-FDG PET/CT as a diagnostic algorithm for the assessment of tumor response in rectal cancer after neoadjuvant chemoradiation therapy (CRT) is very useful. MATERIAL AND METHODS: this was a ...
  • Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study 
    Martínez, María; Jiménez, Sara; Guzman, Florentina; Fernández, Marta; Arizaga, Elena; Sanz, Consuelo (WILEY-HINDAWI, 2022-07)
    BACKGROUND: Due to the high false negative rate (FNR) associated with sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST), the standard surgical treatment for patients with an initially positive ...
  • Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01) 
    Lluch, Ana; Barrios, Carlos-H; Torrecillas, Laura; Ruiz-Borrego, Manuel; Bines, José; Segalla, José; Guerrero-Zotano, Ángel; García-Saenz, José-A; Torres, Roberto; de-La-Haba, Juan; García-Martínez, Elena; Gómez, Henry-L; Llombart, Antonio; Salvador-Bofill, Javier; Baena-Cañada, José-M; Barnadas, Agusti; Calvo, Lourdes; Pérez-Michel, Laura; Ramos, Manuel; Fernández-Pérez, Isaura; Rodríguez-Lescure, Álvaro; Cárdenas, Jesús; Vinholes, Jeferson; Martínez-de-Dueñas, Eduardo; Godes, María-J; Segui, Miguel-A; Antón, Antonio; López-Álvarez, Pilar; Moncayo, Jorge; Amorim, Gilberto; Villar, Esther; Reyes, Salvador; Sampaio, Carlos; Cardemil, Bernardita; Escudero, María-J; Bezares, Susana; Carrasco, Eva; Martín, Miguel; Corona, J; Jara, C; Cardemil, Bernardita; Toro, R; Pimentel, C; Hernando, B; Vicente, Esther; Zagame, L; Gil, M; García-Estevez, L; Rodríguez, C; de-la-Cruz, M-A; Tello, J-M; Campos, S; Lomas, M; Capdevile, D; Campos, M; Margeli, M; Andrés, R; Tusquets, I; Ballesteros, A; Guerrero, A; Argüello, M; Rodríguez, J-L; Muñoz, M; Florian, J; Azevedo, S; Mondragón, R; Peralta, J; Palomo, A-E; Barajas, L-J; Arcusa, A; Carranza, H; García, C; Umbria, C; Ales, José-E; López-Vega, J-M; Romeo, M; Valero, J; Alonso, J-L; Mathias, C; Gutiérrez, Félix; Adrover, E; Núñez, P; Mendiola, C; Cassinello, J; de-la-Huerta, A (AMER SOC CLINICAL ONCOLOGY, 2020-01-20)
    PURPOSE: Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion ...
  • Relationships of Gut Microbiota Composition, Short-Chain Fatty Acids and Polyamines with the Pathological Response to Neoadjuvant Radiochemotherapy in Colorectal Cancer Patients 
    Sánchez-Alcoholado, Lidia; Laborda-Illanes, Aurora; Otero, Ana; Ordoñez, Rafael; González-González, Alicia; Plaza-Andrades, Isaac; Ramos-Molina, Bruno; Gómez-Millán, Jaime; Isabel-Queipo-Ortuño, María (MDPI, 2021-09)
    Emerging evidence has suggested that dysbiosis of the gut microbiota may influence the drug efficacy of colorectal cancer (CRC) patients during cancer treatment by modulating drug metabolism and the host immune response. ...